有没有厄达替尼？厄达替尼价格怎样？

Erdafitinib is approved by the U.S. FDA for the treatment of patients with urothelial carcinoma and locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 gene mutations who have progressed during or after platinum-based chemotherapy, including patients with disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy. Erdafitinib (Balversa) is the first targeted therapy drug approved by the US FDA for advanced or metastatic urothelial cancer. It regulates cell growth and division by targeting genetic changes in fibroblast growth factor receptor (FGFR) to inhibit tumorigenesis and angiogenesis. (Balversa) represents the first personalized treatment option for patients with metastatic urothelial cancer targeting FGFR genetic alterations. The price of the original drug Erdafitinib (Balversa) is relatively high, and many patients say they cannot afford it. Therefore, cost-effective generic drugs have attracted the attention of patients. What is the price of generic drugs of Erdafitinib in India?

Is Erdafitinib available in India? What is the price of generic drug Erdafitinib in India?

If patients want to know the purchasing channels and specific drug prices of erdafitinib, they can consult with domestic reliable overseas medical service companies (such as Medical Travel).

Clinical trials of Erdafitinib

Erdafitinib was approved by the FDA based on a multi-center, open-label single-arm phase II clinical study (BLC2001, NCT02365597 ), this study evaluated the clinical efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma carrying FGFR gene mutations (R248C, S249c, G370c, Y373C) or/and fusions (FCFR3-TACC3, FGFR3BAIAP2L1, FCFR2-BICC1, FGFR2-CASP7). Enrolled patients have received at least first-line chemotherapy, and subjects who have received immunotherapy are also allowed to be enrolled. Results published by ASCO in 2018 showed that after 11 months of follow-up, 21.2% of subjects were still receiving Erdafitinib treatment, the median progression-free survival (PFS) was 5.5 months, and the median overall survival (OS) was 13.8 months. It can be seen from the above clinical trial data that the therapeutic effect of Erdafitinib is very significant.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Related hot articles